Canadian ACTOS® / Pioglitazone Class Action

Important updates

The decision in the Quebec hearing has been reserved and the Ontario hearing was adjourned pending further information requested by the Court. When the decisions of the Courts are rendered, they will be posted here.

The Opt Out Deadline was January 26, 2021 at 11:59 pm.

Introduction

Canadian lawsuits related to the prescription drugs ACTOS®, APO-Pioglitazone and Sandoz-Pioglitazone (collectively referred to as PIO) sought compensation for harm alleged to be associated with the use of the medications, including the development of bladder cancer.

As part of the settlement process, the Québec and Ontario Courts have authorized/certified the following classes for settlement purposes:

Québec Class: All persons resident in Québec who purchased and/or used ACTOS® from August 17, 2000 to the date the Settlement is finally approved by the Courts (the “Class Period”), and their estates, administrators or other legal representatives, heirs or beneficiaries;

Québec Family Class: All family members and/or dependents of Québec Class Members who would have been entitled to assert a claim for compensation in the Québec Action;

Ontario National Class: All persons resident in Canada, excluding residents of Québec, who purchased and/or used ACTOS®, and all persons resident in Canada who purchased and/or used APO-Pioglitazone and/or SANDOZ-Pioglitazone, during the Class Period, and their estates, administrators or other legal representatives, heirs or beneficiaries; and

Ontario National Family Class: All persons who on account of a personal relationship to an Ontario National Class Member are entitled to assert a derivative claim for damages pursuant to the applicable provincial and/or territorial family law legislation.

Frequently Asked Questions

Court Documents

Contact Us

Canadian ACTOS® / Pioglitazone Class Action
c/o CA2 Inc.
9 Prince Arthur Avenue
Toronto, ON M5R 1B2

pio@classaction2.com
Tel: 1-800-538-0009